PEP2BRAIN
Selected peptides as drug candidates directed to pain and neurodegeneration
| Coordinatore | INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
| Nazionalità Coordinatore | Portugal [PT] |
| Totale costo | 659˙895 € |
| EC contributo | 659˙895 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-IAPP-2008 |
| Funding Scheme | MC-IAPP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-03-01 - 2013-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
PT (LISBOA) | coordinator | 248˙037.00 |
| 2 |
SYNOVO GMBH
Organization address
address: Paul Ehrlich Str 15 contact info |
DE (TUEBINGEN) | participant | 123˙876.00 |
| 3 |
UNIVERSITAT DE GIRONA
Organization address
address: PLACA SANT DOMENEC 9 EDIFICI LES ALIGUES contact info |
ES (GIRONA) | participant | 107˙603.00 |
| 4 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 95˙437.00 |
| 5 |
BIOALVO S.A.
Organization address
city: Lisbon contact info |
PT (Lisbon) | participant | 84˙942.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'BLV200703/4 is a small molecule discovered jointly by groups from the University of Lisbon (Portugal) and Girona (Spain) that proved its efficacy in analgesia from behavioural tests in rats. The same molecule was tested in a platform that screens potential pharmacological molecules/compounds for neurodegenerative diseases with positive results. The platform is owned by Bioalvo, SA (Portugal). The preliminary results so far obtained regarding efficacy and toxicology of the molecule are encouraging and the academic inventors and the industrial developers are committed to take it into preclinical tests. However, a previous phase of lead optimisation is needed where a well devised strategy will make use of medicinal chemistry methodologies combined with robust in vitro and in vivo assays, in order to achieve the best pharmacological and ADME/toxicity characteristics for our lead molecule. This requires technology, knowledge and innovation transfer since the inventors and Bioalvo are unable to perform this endeavour on their own. Synovo, a German company expert in ADME/tox tests and the University of Tuebingen, with a group expert in Medicinal Chemistry, joined Bioalvo and the Universities of Lisbon and Girona to transfer all knowledge, technology and innovation necessary to make possible that BLV200703 or one of its future derivatives reaches pre-clinical stage. This project fits the 'Developability Assessment Logic Plan' of BLV200703 as established with a consulting company expert in drug development. Not only all the participants are committed to the success of this product development, they are also committed to two-ways exchange of information and technology that strength their activity in the future. For instance, in the end of this project Bioalvo SA will have a MedChem unit that will strength future development of new products and the Universities of Lisbon and Girona will be able to carry out basic early toxicology tests as part of their research.'